It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
Biologics showed no clear difference in withdrawals due to adverse events 12 to 44 weeks compared with placebo (low certainty).
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).
It is very uncertain whether four‐food elimination diet with omeprazole changes withdrawals due to adverse events at 8 to 12 weeks compared with omeprazole (very low certainty).
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with ureteroscopy with holmium laser or pneumatic lithotripsy (very low certainty).
Shock wave lithotripsy may leads to lower serious adverse events or complications of treatment compared with mini‐percutaneous nephrolithotripsy (low certainty).
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with dissolution therapy (very low certainty).
It is very uncertain whether percutaneous nephrolithotripsy changes serious adverse events or complications of treatments compared with tubeless percutaneous nephrolithotripsy (very low certainty).
The intervention showed no clear difference in risk of adverse events (until time of hospital discharge) (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether potassium citrate changes proportion of participants with adverse events while undergoing… compared with no intervention (very low certainty).
Surgery probably leads to lower proportion of women with adverse events Endometrial ablation versus… compared with LNG‐IUS (moderate certainty).
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).